Community APP Mentorship: Use of Bispecifics in Myeloma

It is with great pleasure that we welcome you to participate in an upcoming mentorship program.
Advanced Practice Providers (APPs), and especially those in community settings, often face limited
access to specialized expertise in rapidly evolving fields like multiple myeloma (MM), yet most patients
receive their care locally. Novel therapies which target the B-Cell Maturation Antigen (BCMA) are highly
effective yet can be daunting for the APP to administer, monitor and manage. Therefore, the International
Myeloma Foundation and Nurse Leadership Board (NLB) members have created a structured mentorship
program that pairs community APPs with experienced academic clinicians. The content directly
addresses these gaps by facilitating practical, real-time learning, and reinforcing adoption of
standardized protocols to effectively manage patients.

The program employs a reciprocal, collaborative peer-mentorship model designed to integrate real-world
experience in MM care with BCMA-targeted bispecific therapy. In just 8 short weeks, mentees will engage
in a curriculum that combines three key components: self-guided learning modules, mentor-led case
discussions, and a practice-based project culminating in a final presentation. Each mentee is paired oneto-one with an experienced academic mentor to receive personalized guidance.

Learning Objectives:

• Enhance clinical knowledge and skills of community-based APPs in initiating and managing
  BCMA-targeted bispecific therapies, including step-up dosing, early toxicity recognition, infection
  prevention, and patient education.
• Facilitate structured mentorship by pairing community APPs with experienced academic
  clinicians to provide ongoing guidance, case-based learning, and real-time support for complex
  clinical decision-making.
• Strengthen care coordination and transitions of care by implementing standardized protocols and
  communication pathways that ensure safe, continuous management of patients moving between
  academic and community oncology settings

Recruitment for this program will take place August 1-September 15, 2026, with the first cohort
beginning in October

About the Symposium:

Treatments in multiple myeloma continue to evolve, transforming care across settings. This 1.5 CNE symposium explores novel combination regimens, infection risk, community-based coordination, and innovations in treatment administration. Through case studies, expert nurse presenters will share their best practices for management of smoldering myeloma, treatment sequencing, minimal residual disease, and adverse event management. Attendees will gain actionable insights and free downloadable tools to optimize care delivery, enhance patient outcomes, and navigate emerging therapies with confidence.